Mobile

A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetes

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-004722-16

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To demonstrate the efficacy of vildagliptin MR (12.5 mg bid or 25 mg bid) as add-on therapy to metformin in patients with T2DM by testing the hypothesis that the HbA1c reduction with vildagliptin MR added to metformin is superior to that of placebo added to metformin after 24 weeks of treatment.

Critère d'inclusion

  • Type II Diabetes

Liens